Mannan-binding lectin (MBL) is a plasma protein involved in the innate immune response. It binds to a number of micro-organisms and promotes killing of these through complement activation either directly or through opsonization. Clinical evidence indicates that in a variety of situations genetically determined low MBL levels are associated with increased susceptibility to infections. Infusions of plasma-derived MBL into MBL-deficient individuals was found to be safe in preliminary trials, but we considered that sufficient production and product safety could only be achieved through synthesis of recombinant MBL. A transfected human cell line produces MBL showing the same biological activity as plasma-derived MBL, and an essentially identical profile on MS. The production has been scaled up and clinical trials will start this year.
Skip Nav Destination
Conference Article| August 01 2003
Recombinant mannan-binding lectin (MBL) for therapy
Biochem Soc Trans (2003) 31 (4): 763–767.
- Views Icon Views
- Share Icon Share
J.C. Jensenius, P.H. Jensen, K. McGuire, J.L. Larsen, S. Thiel; Recombinant mannan-binding lectin (MBL) for therapy. Biochem Soc Trans 1 August 2003; 31 (4): 763–767. doi: https://doi.org/10.1042/bst0310763
Download citation file: